By Fineline Cube 
Anhui Anke Biotechnology (Group) Co., Ltd. and PersonGen BioTherapeutics (Suzhou) Co., Ltd. (PersonGen) announced today a dual‑track strategic partnership that combines a RMB 30 million capital injection with an exclusive agency agreement for PersonGen’s lead product, PA3‑17 injection, across the Greater China region (Mainland, Hong Kong, Macau, Taiwan).
Deal Structure
| Element | Details |
|---|---|
| Capital increase | AnkeBio, now the second‑largest shareholder, will invest RMB 30 million in PersonGen, deepening its equity stake. |
| Exclusive agency rights | AnkeBio obtains sole commercialisation rights for PA3‑17 injection in Greater China. |
| Strategic shift | Moves from early‑stage R&D collaboration to a “capital‑binding + joint‑commercial‑operation” model. |
| Timeline | Investment and agency agreement effective Q4 2025; commercial launch targeted 2027 pending Phase 2 read‑out. |
Product Spotlight – PA3‑17 Injection
- Therapeutic class: Autologous CAR‑T cell therapy targeting CD7.
- Innovation: First IND‑approved CD7 CAR‑T that avoids gene editing, eliminating fratricide and tumour‑cell contamination while employing a proprietary quality‑control platform.
- Clinical data: Phase 1 trial showed favourable safety and high complete‑response rates in relapsed/refractory T‑ALL and T‑LBL patients.
- Regulatory status: Granted Breakthrough Therapy Designation (BTD) by the NMPA’s Center for Drug Evaluation (CDE) and now advancing in a pivotal Phase 2 study.
Market Opportunity
- T‑ALL/T‑LBL unmet need: Approximately 2,500 new paediatric and adult T‑cell acute leukaemia cases are diagnosed annually in China, with a relapse rate > 30 % after standard chemotherapy.
- Pricing potential: Early market modelling suggests a treatment price of ¥1.5–¥2.0 million per course, comparable to imported CAR‑T products but with a domestic supply‑chain advantage.
- Revenue outlook: Assuming a 5 % market capture of the relapsed/refractory T‑cell leukaemia segment, AnkeBio could generate ¥3–¥5 billion in net sales by 2030.
Strategic Implications
- Capital‑backed commercialisation: The RMB 30 million infusion provides PersonGen with the cash runway to accelerate Phase 2 enrolment and manufacturing scale‑up.
- AnkeBio’s commercial muscle: Leveraging its established sales network and regulatory expertise, AnkeBio can fast‑track market entry across the Greater China region.
- Pipeline synergies: The partnership creates a platform for future CAR‑T collaborations, potentially expanding into other CD‑targeted programmes.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the capital increase, commercial launch timeline, pricing, and market potential for PA3‑17. Actual results may differ due to clinical outcomes, regulatory review, competitive dynamics, and execution of the partnership.-Fineline Info & Tech